8-(Phenyl)triazolyloctahydroxamic acid | 1048363-58-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 8-(Phenyl)triazolyloctahydroxamic acid
• 英文别名: N-hydroxy-8-(4-phenyltriazol-1-yl)octanamide
• CAS: 1048363-58-1
• 化学式: C₁₆H₂₂N₄O₂
• 分子量: 302.376
• InChiKey: BINBEBYLQADFMB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  22
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  80
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  8-(4-phenyl-1H-1,2,3-triazol-1-yl)-N-(trityloxy)octanamide 在 茴香硫醚 、 三氟乙酸 、 silica gel 作用下， 以 二氯甲烷 、 甲醇 为溶剂， 以51%的产率得到8-(Phenyl)triazolyloctahydroxamic acid
  参考文献：
  名称：

  Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group

  摘要：

  Histone deacetylase inhibitors (HDACi) are endowed with plethora of biological functions including anti-proliferative, anti-inflammatory, anti-parasitic, and cognition-enhancing activities. Parsing the structure activity relationship (SAR) for each disease condition is vital for long-term therapeutic applications of HDACi. We report in the present study specific cap group substitution patterns and spacer-group chain lengths that enhance the antimalarial and antileishmanial activity of aryltriazolylhydroxamates-based HDACi. We identified many compounds that are several folds selectively cytotoxic to the plasmodium parasites compared to standard HDACi. Also, a few of these compounds have antileishmanial activity that rivals that of miltefosine, the only currently available oral agent against visceral leishmaniasis. The anti-parasite properties of several of these compounds tracked well with their anti-HDAC activities. The results presented here provide further evidence on the suitability of HDAC inhibition as a viable therapeutic option to curb infections caused by apicomplexan protozoans and trypanosomatids. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2009.10.042

文献信息

• Antimalarial and antileishmanial activities of histone deacetylase inhibitors with triazole-linked cap group
  作者：Vishal Patil、William Guerrant、Po C. Chen、Berkley Gryder、Derek B. Benicewicz、Shabana I. Khan、Babu L. Tekwani、Adegboyega K. Oyelere

  DOI：10.1016/j.bmc.2009.10.042

  日期：2010.1

  Histone deacetylase inhibitors (HDACi) are endowed with plethora of biological functions including anti-proliferative, anti-inflammatory, anti-parasitic, and cognition-enhancing activities. Parsing the structure activity relationship (SAR) for each disease condition is vital for long-term therapeutic applications of HDACi. We report in the present study specific cap group substitution patterns and spacer-group chain lengths that enhance the antimalarial and antileishmanial activity of aryltriazolylhydroxamates-based HDACi. We identified many compounds that are several folds selectively cytotoxic to the plasmodium parasites compared to standard HDACi. Also, a few of these compounds have antileishmanial activity that rivals that of miltefosine, the only currently available oral agent against visceral leishmaniasis. The anti-parasite properties of several of these compounds tracked well with their anti-HDAC activities. The results presented here provide further evidence on the suitability of HDAC inhibition as a viable therapeutic option to curb infections caused by apicomplexan protozoans and trypanosomatids. (C) 2009 Elsevier Ltd. All rights reserved.